Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences BioEngineering 2017: BioMEMS, 3D-BioPrinting & Synthetic Biology

Mehmet Toner's Biography



Mehmet Toner, Helen Andrus Benedict Professor of Biomedical Engineering; Director, BioMEMS Center, Mass General Hospital and Harvard Medical School

Mehmet Toner is Professor of Surgery (Biomedical Engineering) at the Massachusetts General Hospital, Harvard Medical School, and is the founding director of the NIH BioMEMS Resource Center. Dr. Toner was born in Istanbul, Turkey in July 1958. Dr. Toner received a Bachelor of Science degree from Istanbul Technical University in 1983 and an M.S. degree from the Massachusetts Institute of Technology (MIT) in 1985, both in Mechanical Engineering. He subsequently completed his Ph.D. in Medical Engineering at the Harvard-MIT Division of Health Sciences and Technology (HST) in 1989. He joined the faculty at the Massachusetts General Hospital (MGH) and Harvard Medical School as an Assistant Professor of Biomedical Engineering in 1989, and was promoted to Associate Professor in 1996, and to Professor in 2002. Dr. Toner has a joint appointment as a Professor of Health Sciences and Technology at the Harvard-MIT Division of HST. Dr. Toner serves as a member of the Senior Scientific Staff at the Shriners Hospital for Children. He is a co-founder of the Center for Engineering in Medicine, and founder of the NIH BioMicroElectroMechanical Systems (BioMEMS) Resource Center at the MGH. He is also the Director of the Biomedical Engineering Research and Education Program for physicians at MGH. Dr Toner is a member of many national and international professional committees, and serves on the editorial board of many scientific journals including Cryobiology, Cryo-Letters, Cell Preservation Technology, Annual Reviews in Biomedical Engineering, and Nanomedicine. He has served on many national and international panels and review boards, including National Institutes of Health (NIH) Study Sections, National Science Foundation (NSF) CAREER Award panels, NSF Nanoscience panel, NIH Nanotechnology and Tissue Engineering panel, and several DARPA strategic planning panels. In 1994, he was recognized by the YC Fung Faculty Award in Bioengineering from the American Society of Mechanical Engineers (ASME). In 1995, he received the Whitaker Foundation Special Opportunity Award. In 1997, he won the John F and Virginia B Taplin Faculty Fellow Award given by Harvard and MIT. In 1998, Dr. Toner was selected to become a Fellow of the American Institute of Medical and Biological Engineering. Dr. Toner serves on the Scientific Advisory Board of multiple biotechnology and medical device companies, and has been involved as a scientific founder of multiple startup companies.

Mehmet Toner Image

Microfluidics to Isolate Single and Clusters of Rare Circulating Tumor Cells to Manage Cancer Patients

Thursday, 16 March 2017 at 10:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Viable tumor-derived circulating tumor cells (CTCs) have been identified in peripheral blood from cancer patients and are not only the origin of intractable metastatic disease but also marker for early cancer. However, the ability to isolate CTCs has proven to be difficult due to the exceedingly low frequency of CTCs in circulation. As a result their clinical use until recently has been limited to prognosis with limited clinical utility.  More recently, we introduced several microfluidic methods to improve the sensitivity of rare event CTC isolation, a strategy that is particularly attractive because it can lead to efficient purification of viable CTCs from unprocessed whole blood. The micropost CTC-Chip (µpCTC-Chip) relies on laminar flow of blood cells through anti-EpCAM antibody-coated microposts, whereas the herringbone CTC-Chip (HbCTC-Chip) uses micro-vortices generated by herringbone-shaped grooves to efficiently direct cells toward antibody-coated surfaces. These antigen-dependent CTC isolation approaches, also called “positive selection”, led to the development of a third technology, which is tumor marker free (or antigen-independent) sorting of CTCs. We call this integrated microfluidic system the CTC-iChip, based on the inertial focusing strategy, which allows positioning of cells in a near-single file line, such that they can be precisely deflected using minimal magnetic force.

Microfluidics to Isolate Single and Clusters of Rare Circulating Tumor Cells to Manage Cancer Patients

Thursday, 16 March 2017 at 10:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Viable tumor-derived circulating tumor cells (CTCs) have been identified in peripheral blood from cancer patients and are not only the origin of intractable metastatic disease but also marker for early cancer. However, the ability to isolate CTCs has proven to be difficult due to the exceedingly low frequency of CTCs in circulation. As a result their clinical use until recently has been limited to prognosis with limited clinical utility.  More recently, we introduced several microfluidic methods to improve the sensitivity of rare event CTC isolation, a strategy that is particularly attractive because it can lead to efficient purification of viable CTCs from unprocessed whole blood. The micropost CTC-Chip (µpCTC-Chip) relies on laminar flow of blood cells through anti-EpCAM antibody-coated microposts, whereas the herringbone CTC-Chip (HbCTC-Chip) uses micro-vortices generated by herringbone-shaped grooves to efficiently direct cells toward antibody-coated surfaces. These antigen-dependent CTC isolation approaches, also called “positive selection”, led to the development of a third technology, which is tumor marker free (or antigen-independent) sorting of CTCs. We call this integrated microfluidic system the CTC-iChip, based on the inertial focusing strategy, which allows positioning of cells in a near-single file line, such that they can be precisely deflected using minimal magnetic force.


Add to Calendar ▼2017-03-16 00:00:002017-03-17 00:00:00Europe/LondonBioEngineering 2017: BioMEMS, 3D-BioPrinting and Synthetic BiologyBioEngineering 2017: BioMEMS, 3D-BioPrinting and Synthetic Biology in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com